JP Morgan Chase’s Evelo Biosciences, Inc. Common Stock EVLO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-3,162
| Closed | -$12.4K | – | 8125 |
|
|
2023
Q3 | $12.4K | Buy |
3,162
+2,962
| +1,481% | +$20.2K | ﹤0.01% | 6204 |
|
|
2023
Q2 | $650 | Buy |
200
+4
| +2% | +$12 | ﹤0.01% | 6512 |
|
|
2023
Q1 | $1K | Buy |
196
+19
| +11% | +$293 | ﹤0.01% | 6592 |
|
|
2022
Q4 | $6K | Sell |
177
-183
| -51% | -$7.24K | ﹤0.01% | 6143 |
|
|
2022
Q3 | $15K | Buy |
360
+107
| +42% | +$4.89K | ﹤0.01% | 5888 |
|
|
2022
Q2 | $11K | Sell |
253
-772
| -75% | -$35.8K | ﹤0.01% | 6021 |
|
|
2022
Q1 | $69K | Buy |
1,025
+209
| +26% | +$17.4K | ﹤0.01% | 5668 |
|
|
2021
Q4 | $99K | Buy |
816
+234
| +40% | +$39.5K | ﹤0.01% | 5690 |
|
|
2021
Q3 | $82K | Sell |
582
-1
| -0.2% | -$198 | ﹤0.01% | 5672 |
|
|
2021
Q2 | $160K | Sell |
583
-2,813
| -83% | -$710K | ﹤0.01% | 5344 |
|
|
2021
Q1 | $726K | Buy |
3,396
+777
| +30% | +$215K | ﹤0.01% | 4445 |
|
|
2020
Q4 | $633K | Buy |
2,619
+2,246
| +602% | +$278K | ﹤0.01% | 4239 |
|
|
2020
Q3 | $36K | Buy |
373
+137
| +58% | +$12.5K | ﹤0.01% | 5031 |
|
|
2020
Q2 | $23K | Buy |
236
+16
| +7% | +$1.4K | ﹤0.01% | 5011 |
|
|
2020
Q1 | $16K | Sell |
220
-6
| -3% | -$571 | ﹤0.01% | 4993 |
|
|
2019
Q4 | $18K | Buy |
226
+1
| +0.4% | +$112 | ﹤0.01% | 5334 |
|
|
2019
Q3 | $27K | Buy |
225
+36
| +19% | +$4.95K | ﹤0.01% | 5345 |
|
|
2019
Q2 | $34K | Buy |
189
+21
| +13% | +$3.4K | ﹤0.01% | 5317 |
|
|
2019
Q1 | $27K | Sell |
168
-8
| -5% | -$1.58K | ﹤0.01% | 5331 |
|
|
2018
Q4 | $46K | Buy |
176
+114
| +184% | +$22.9K | ﹤0.01% | 5112 |
|
|
2018
Q3 | $15K | Buy |
62
+8
| +15% | +$2.09K | ﹤0.01% | 5465 |
|
|
2018
Q2 | $13K | Buy |
+54
| New | +$15.7K | ﹤0.01% | 5352 |
|
